Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech vs. Shorts -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (202)	8/30/1999 9:57:00 PM
From: Pseudo Biologist	Respond to of 427

V1, thanks a lot for the updates on analysts' opinions. According to (free) Bloomberg, Piper also kept a strong buy: quote.bloomberg.com Bad day indeed. Unfortunately, this is one of those situations where it is easier (if not right) to come up with all sorts of negative spin to explain how "something like this can happen." PB

To: Vector1 who wrote (202)	8/30/1999 10:21:00 PM
From: kendall harmon	Read Replies (1) \| Respond to of 427

CLTR--Ginsberg reiterated a strong buy Princeton, New Jersey, Aug. 30 (Bloomberg Data) -- Coulter Pharmaceutical Inc. (CLTR US) was reiterated ''strong buy'' by analyst Peter L. Ginsberg at U.S. Bancorp Piper Jaffray. The near-term price target is $36 per share.

To: Vector1 who wrote (202)	8/31/1999 10:25:00 AM
From: Gordon James	Read Replies (1) \| Respond to of 427

V1, Thanks for the analyst info - not surprising that Ende bolted, the short-tilted articles were quoting him a lot back before the filing regarding his unease about whether the filing would happen on time. Agree with you on all points that you've made on this: - Should be open season on CLTR for awhile for the shorts - Company credibility is increasingly in question now, detractors will pound this - Shorts have turned out to be right at this point for a lot of wrong reasons, they're still yammering about some things that don't sound related to this delay... I wish they'd make themselves useful and shed some more light on it and less FUD -The question is how can something like this happen. Well put. The TSC article talks about Mac files needing to be reformatted to PC. ???? In Bloomberg reports, Bigham pointedly states that they could have met these additional requirements had they known about them. Was this really some last-minute bureaucratic curveball, or did somebody at Coulter drop the ball, or what? If you have any more information on specifically what are the seven points of contention, I'd be interested in seeing them. That said, I'm as convinced as ever that Bexxar will be approved and used widely (unless the Bexxar delays continue to the point that Zevalin is approved first, I have some unanswered questions about orphan drug status between the two that I haven't bothered to get answered due to Bexxar's time-to-market lead). So my powder is dry now, and I'm hoping for enough FUD over the next few weeks to create some excellent opportunities to load back up... THis has been a bad day. No sh*t... :-( Gordon